Apotex Inc. has followed Sandoz in urging the Supreme Court to review an appeals court ruling that delays the launch of a biosimilar until six months after FDA licensure.
Apotex filed a petition on Sept. 9 challenging the US Court of Appeals for the Federal Circuit's decision...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?